On February 28, 2023,Deputy Director-General WangXiang from the High-Tech Department of the National Development and Reform Commission,A delegation of three individualsand relevant leaders from the province, city, and high-tech zone.visited Maxin Company for guidance and research, accompanied by
General ManagerWang Xiaoya, Deputy General Manager of OperationsLin Qixin, Deputy General Manager of R&DYang Qinghaiand other leadersalso participated in this event.
General Manager Wang first introduced Maxin’s main business and products, technology platforms, independent innovation achievements, and future plans to Deputy Director-General Wang.。General Manager Wang stated that as a wholly-owned subsidiary of Jiuzhou Bio under the Sinopharm Group, Maxin Bio has always been committed to revitalizing the nation’s in vitro diagnostic (IVD) industry, striving to catch up and surpass, and working tirelessly.focusing on innovation,Facing the new landscape of precision medicine development,Maxin closely follows industry frontiers, continuously advancing product automation, intelligence, and high-performance development.Currently,it has establishedCompleteda diversified product platform, forging a unique development path.
During the visit, Deputy Director-General Wang inquired in detailand asked aboutthe challenges and pain points Maxin encountered in its innovation process.He pointed out that enterprisesThey shouldstrive to break through core ‘bottleneck’ technologies, alwaysmust grasp the initiative in development。
General Manager Wang proudly toldDeputy Director-General Wang thatMaxinas a national-level high-tech specialized enterprise, firmly adheres to the path of independent innovation.In the field of tumor pathology diagnosis, it has successfullybroken the technological monopoly of Europe and America, developing hundreds of pathology diagnostic-gradeantibodies,and launched the first fully automated pathology staining system in China with complete independent intellectual property rights, possessing the technical strength to compete with multinational corporations.
Deputy Director-General Wang fully affirmed Maxin’s achievements in independent innovation andencouraged us to continue striving and make greater contributions to the transformation and upgrading of the national high-tech industry.
Visiting Maxin’s Laboratory
Under the enthusiastic guidance of the company’s leaders,Deputy Director-General Wang and his delegationalso visited Maxin’s laboratory with great interest. Deputy General Manager Yang introduced toDeputy Director-General Wang the monoclonal antibody R&D technology, the application of immunohistochemistry in pathology diagnosis, and the phased achievements of Maxin’s R&D team in artificial intelligence.
Deputy Director-General Wang XiangHe highly praised Maxin’s innovation and development achievements. He pointed out that biotechnology and products are the cornerstone of the medical and health industry and are currently a key focus and supported industry by the state. He hopes that Maxin will further leverage its advantages in technological innovation, increase investment in scientific research and development, and contribute to the company’s future scientific and sustainable development and the revitalization of the national biopharmaceutical industry.
Live up to expectations and forge ahead
This guidance and research visit by leaders from the National Development and Reform Commission and other levels fully demonstrates the government’s care and support for Maxin Company. Maxin people will live up to expectations and forge ahead, continuously improving product technology and user service levels, supporting precision medicine, and benefiting global cancer patients.
